Clinical Scorecard: Top 10 Evidence-Based Essentials in Dermatology

At a Glance

Key Highlights

• 2024 AAD Acne Guideline strongly recommends benzoyl peroxide, topical retinoids, topical antibiotics, oral doxycycline, and oral isotretinoin.
• Novel therapies for adult atopic dermatitis include nemolizumab and JAK inhibitors such as abrocitinib, baricitinib, and upadacitinib.
• Biologics like brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa show highest PASI response rates in moderate-to-severe psoriasis.

Guideline-Based Recommendations

Diagnosis

• Use validated severity instruments such as PASI for psoriasis clinical trials and EASI for eczema clinical trials.
• Clinical assessment remains primary; PASI is recommended for research rather than routine clinical practice.

Management

• For acne, initiate treatment with benzoyl peroxide, topical retinoids, topical antibiotics, oral doxycycline, or oral isotretinoin per 2024 AAD guidelines.
• For moderate-to-severe atopic dermatitis, consider nemolizumab plus topical therapy and JAK inhibitors (abrocitinib, baricitinib, upadacitinib).
• For psoriasis, utilize biologics with highest efficacy including brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa.
• Topical ruxolitinib cream is FDA-approved for short-term and intermittent longer-term treatment of mild to moderate atopic dermatitis in patients aged 2 years and older.

Monitoring & Follow-up

• Monitor clinical response using validated severity indices in trials; clinical monitoring guided by symptom improvement and side effect profile in practice.
• Regular assessment for treatment efficacy and adverse effects, especially with systemic therapies and biologics.

Risks

• Consider immunocompetence status before prescribing topical ruxolitinib cream.
• Monitor for potential adverse effects associated with systemic antibiotics, isotretinoin, biologics, and JAK inhibitors.

Patient & Prescribing Data

Patients with acne vulgaris aged 9 years and older, adults and adolescents with moderate-to-severe atopic dermatitis, and patients with moderate-to-severe plaque psoriasis.

Topical retinoids like trifarotene are FDA-approved for acne in patients aged 9+, while systemic therapies including oral doxycycline and isotretinoin are strongly recommended. Biologics and JAK inhibitors provide effective options for moderate-to-severe psoriasis and atopic dermatitis.

Clinical Best Practices

• Incorporate evidence-based guidelines from AAD and NPF for treatment selection.
• Use validated severity scoring tools primarily in clinical trials to assess treatment efficacy.
• Tailor therapy based on disease severity, patient age, and comorbidities.
• Consider novel therapies and updated guidelines to optimize patient outcomes.
• Ensure patient education on treatment adherence and monitoring for adverse effects.

References

• American Academy of Dermatology Acne Guideline 2024
• American Academy of Dermatology Adult Atopic Dermatitis Guideline Updates 2023-2025
• Joint AAD-National Psoriasis Foundation Psoriasis Guideline
• POETYK PSO-2 Trial Data
• ARCADIA 1 and ARCADIA 2 Trials
• US Food and Drug Administration Labeling for Trifarotene and Ruxolitinib
• JAMA Dermatology Meta-analysis on Biologics for Psoriasis
• Harmonising Outcome Measures for Eczema Initiative